Latest Alba Therapeutics Corporation Stories
FRAZER, Pa., Feb. 9, 2011 /PRNewswire/ -- Cephalon, Inc.
BALTIMORE, March 17 /PRNewswire/ -- Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.
BALTIMORE, Nov. 11 /PRNewswire/ -- Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease.
ORLANDO, Fla., Oct. 7 /PRNewswire/ -- Alba Therapeutics Corporation presented results from two clinical studies this week at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting.
BALTIMORE, Oct. 2 /PRNewswire/ -- Alba Therapeutics Corporation today announced the promotions of Linda Arterburn, PhD, Francisco Leon, MD, PhD, Roberto Allen, Esquire, Mark Ginski, PhD, and Kate Huber.
- The act of sweetening by admixture of some saccharine substance.